Limosa Immunodiagnostics
Platform for high-sensitivity, single-cell T-cell proliferation analysis.
The founders
FB
GV
The company
Limosa Immunodiagnostics is commercialising ProliSpot, a method that measures immune responses by detecting cell division at single-cell resolution. The company says the assay needs smaller blood samples and returns results faster than methods such as ELISpot, which measure cytokine secretion.
ProliSpot is already sold as a Research Use Only assay through a partnership with Baseclick GmbH, which gives the company early revenue from immunology, vaccinology and oncology researchers. Its most advanced clinical application, a test for latent tuberculosis in people with weakened immune systems, has shown positive results in initial clinical studies, according to the company.
Limosa was founded in 2026 as a spin-off from the University of Groningen and signed an exclusive licensing agreement with the university in April 2026. It then secured an investment from Future Tech Ventures, supplemented by a grant.
Co-founders Geert van den Bogaart and Frans Bianchi both studied at the University of Groningen, the university that licensed ProliSpot to the company. Rinse de Boer and CEO Daphne Gengler are also named among the founders.
Who else is building in this space
Companies working on the same thing, at every stage.
Scale-up
Developing novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system
Rapid genomic biomarker detection for precision oncology
In-vitro immunodiagnostic devices for quantitative analysis
Lateral flow test development and manufacturing services
Developing ground-breaking diagnostics technologies that provide rapid answers right at the patient’s bedside
Developing the first device for non-invasive white cell monitoring
Thousands more founded every month.
Dealroom tracks new companies as they appear — founders, funding and signals, over the API or in the platform.